GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemagen Diagnostics Inc (OTCPK:HMGN) » Definitions » Return-on-Tangible-Asset

Hemagen Diagnostics (Hemagen Diagnostics) Return-on-Tangible-Asset : -26.27% (As of Sep. 2012)


View and export this data going back to . Start your Free Trial

What is Hemagen Diagnostics Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Hemagen Diagnostics's annualized Net Income for the quarter that ended in Sep. 2012 was $-0.65 Mil. Hemagen Diagnostics's average total tangible assets for the quarter that ended in Sep. 2012 was $2.48 Mil. Therefore, Hemagen Diagnostics's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2012 was -26.27%.

The historical rank and industry rank for Hemagen Diagnostics's Return-on-Tangible-Asset or its related term are showing as below:

HMGN's Return-on-Tangible-Asset is not ranked *
in the Biotechnology industry.
Industry Median: -40.42
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Hemagen Diagnostics Return-on-Tangible-Asset Historical Data

The historical data trend for Hemagen Diagnostics's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemagen Diagnostics Return-on-Tangible-Asset Chart

Hemagen Diagnostics Annual Data
Trend Sep03 Sep04 Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.59 -19.05 -4.40 -28.12 -34.03

Hemagen Diagnostics Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.28 -53.92 -37.68 -20.65 -26.27

Competitive Comparison of Hemagen Diagnostics's Return-on-Tangible-Asset

For the Biotechnology subindustry, Hemagen Diagnostics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemagen Diagnostics's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemagen Diagnostics's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Hemagen Diagnostics's Return-on-Tangible-Asset falls into.



Hemagen Diagnostics Return-on-Tangible-Asset Calculation

Hemagen Diagnostics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Sep. 2012 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Sep. 2012 )  (A: Sep. 2011 )(A: Sep. 2012 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Sep. 2012 )  (A: Sep. 2011 )(A: Sep. 2012 )
=-0.907/( (2.888+2.443)/ 2 )
=-0.907/2.6655
=-34.03 %

Hemagen Diagnostics's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2012 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2012 )  (Q: Jun. 2012 )(Q: Sep. 2012 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2012 )  (Q: Jun. 2012 )(Q: Sep. 2012 )
=-0.652/( (2.521+2.443)/ 2 )
=-0.652/2.482
=-26.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2012) net income data.


Hemagen Diagnostics  (OTCPK:HMGN) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Hemagen Diagnostics Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Hemagen Diagnostics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemagen Diagnostics (Hemagen Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
9033 Red Branch Road, Columbia, MD, USA, 21045
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.
Executives
Howard F Curd director

Hemagen Diagnostics (Hemagen Diagnostics) Headlines

No Headlines